PMC:7200337 / 94044-94678 JSONTXT

{"project":"2_test","denotations":[{"id":"32505227-21047436-46575418","span":{"begin":287,"end":291},"obj":"21047436"},{"id":"32505227-16318725-46575419","span":{"begin":304,"end":308},"obj":"16318725"},{"id":"32505227-15220038-46575420","span":{"begin":329,"end":333},"obj":"15220038"},{"id":"32505227-14983044-46575421","span":{"begin":366,"end":370},"obj":"14983044"},{"id":"32505227-17620608-46575422","span":{"begin":384,"end":388},"obj":"17620608"},{"id":"32505227-26404138-46575423","span":{"begin":418,"end":422},"obj":"26404138"},{"id":"32505227-31130102-46575424","span":{"begin":436,"end":440},"obj":"31130102"},{"id":"32505227-25456101-46575425","span":{"begin":455,"end":459},"obj":"25456101"},{"id":"T46722","span":{"begin":287,"end":291},"obj":"21047436"},{"id":"T13757","span":{"begin":304,"end":308},"obj":"16318725"},{"id":"T32153","span":{"begin":329,"end":333},"obj":"15220038"},{"id":"T40642","span":{"begin":366,"end":370},"obj":"14983044"},{"id":"T65482","span":{"begin":384,"end":388},"obj":"17620608"},{"id":"T96040","span":{"begin":418,"end":422},"obj":"26404138"},{"id":"T25280","span":{"begin":436,"end":440},"obj":"31130102"},{"id":"T65647","span":{"begin":455,"end":459},"obj":"25456101"}],"text":"While vaccines are being developed to educate a person’s immune system to make their own nAbs against SARS-CoV-2, there is interest in using adoptive transfer of nAbs as a therapeutic approach (Figure 6D). This strategy has already proven to be effective against SARS-CoV-1 (Cao et al., 2010, Ho et al., 2005, ter Meulen et al., 2004, Park et al., 2020, Sui et al., 2004, Zhu et al., 2007) and MERS-CoV (Forni et al., 2015, Jia et al., 2019, Ying et al., 2015). In the case of SARS-CoV-2, these efforts are primarily centered on identifying nAbs made during natural infections or generating nAbs through animal vaccination approaches."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T735","span":{"begin":57,"end":70},"obj":"Body_part"}],"attributes":[{"id":"A735","pred":"fma_id","subj":"T735","obj":"http://purl.org/sig/ont/fma/fma9825"}],"text":"While vaccines are being developed to educate a person’s immune system to make their own nAbs against SARS-CoV-2, there is interest in using adoptive transfer of nAbs as a therapeutic approach (Figure 6D). This strategy has already proven to be effective against SARS-CoV-1 (Cao et al., 2010, Ho et al., 2005, ter Meulen et al., 2004, Park et al., 2020, Sui et al., 2004, Zhu et al., 2007) and MERS-CoV (Forni et al., 2015, Jia et al., 2019, Ying et al., 2015). In the case of SARS-CoV-2, these efforts are primarily centered on identifying nAbs made during natural infections or generating nAbs through animal vaccination approaches."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T97","span":{"begin":57,"end":70},"obj":"Body_part"}],"attributes":[{"id":"A97","pred":"uberon_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/UBERON_0002405"}],"text":"While vaccines are being developed to educate a person’s immune system to make their own nAbs against SARS-CoV-2, there is interest in using adoptive transfer of nAbs as a therapeutic approach (Figure 6D). This strategy has already proven to be effective against SARS-CoV-1 (Cao et al., 2010, Ho et al., 2005, ter Meulen et al., 2004, Park et al., 2020, Sui et al., 2004, Zhu et al., 2007) and MERS-CoV (Forni et al., 2015, Jia et al., 2019, Ying et al., 2015). In the case of SARS-CoV-2, these efforts are primarily centered on identifying nAbs made during natural infections or generating nAbs through animal vaccination approaches."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T537","span":{"begin":102,"end":110},"obj":"Disease"},{"id":"T538","span":{"begin":263,"end":271},"obj":"Disease"},{"id":"T539","span":{"begin":477,"end":485},"obj":"Disease"},{"id":"T540","span":{"begin":566,"end":576},"obj":"Disease"}],"attributes":[{"id":"A537","pred":"mondo_id","subj":"T537","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A538","pred":"mondo_id","subj":"T538","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A539","pred":"mondo_id","subj":"T539","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A540","pred":"mondo_id","subj":"T540","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"While vaccines are being developed to educate a person’s immune system to make their own nAbs against SARS-CoV-2, there is interest in using adoptive transfer of nAbs as a therapeutic approach (Figure 6D). This strategy has already proven to be effective against SARS-CoV-1 (Cao et al., 2010, Ho et al., 2005, ter Meulen et al., 2004, Park et al., 2020, Sui et al., 2004, Zhu et al., 2007) and MERS-CoV (Forni et al., 2015, Jia et al., 2019, Ying et al., 2015). In the case of SARS-CoV-2, these efforts are primarily centered on identifying nAbs made during natural infections or generating nAbs through animal vaccination approaches."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T969","span":{"begin":46,"end":47},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T970","span":{"begin":57,"end":70},"obj":"http://purl.obolibrary.org/obo/UBERON_0002405"},{"id":"T971","span":{"begin":170,"end":171},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T972","span":{"begin":220,"end":223},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T973","span":{"begin":604,"end":610},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_33208"}],"text":"While vaccines are being developed to educate a person’s immune system to make their own nAbs against SARS-CoV-2, there is interest in using adoptive transfer of nAbs as a therapeutic approach (Figure 6D). This strategy has already proven to be effective against SARS-CoV-1 (Cao et al., 2010, Ho et al., 2005, ter Meulen et al., 2004, Park et al., 2020, Sui et al., 2004, Zhu et al., 2007) and MERS-CoV (Forni et al., 2015, Jia et al., 2019, Ying et al., 2015). In the case of SARS-CoV-2, these efforts are primarily centered on identifying nAbs made during natural infections or generating nAbs through animal vaccination approaches."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T312","span":{"begin":293,"end":295},"obj":"Chemical"}],"attributes":[{"id":"A312","pred":"chebi_id","subj":"T312","obj":"http://purl.obolibrary.org/obo/CHEBI_49648"}],"text":"While vaccines are being developed to educate a person’s immune system to make their own nAbs against SARS-CoV-2, there is interest in using adoptive transfer of nAbs as a therapeutic approach (Figure 6D). This strategy has already proven to be effective against SARS-CoV-1 (Cao et al., 2010, Ho et al., 2005, ter Meulen et al., 2004, Park et al., 2020, Sui et al., 2004, Zhu et al., 2007) and MERS-CoV (Forni et al., 2015, Jia et al., 2019, Ying et al., 2015). In the case of SARS-CoV-2, these efforts are primarily centered on identifying nAbs made during natural infections or generating nAbs through animal vaccination approaches."}

{"project":"LitCovid-PubTator","denotations":[{"id":"3092","span":{"begin":239,"end":241},"obj":"Gene"},{"id":"3093","span":{"begin":71,"end":73},"obj":"Gene"},{"id":"3094","span":{"begin":35,"end":37},"obj":"Gene"},{"id":"3095","span":{"begin":102,"end":112},"obj":"Species"},{"id":"3096","span":{"begin":263,"end":271},"obj":"Species"},{"id":"3098","span":{"begin":477,"end":487},"obj":"Species"},{"id":"3099","span":{"begin":89,"end":93},"obj":"Chemical"},{"id":"3100","span":{"begin":162,"end":166},"obj":"Chemical"},{"id":"3101","span":{"begin":541,"end":545},"obj":"Chemical"},{"id":"3102","span":{"begin":591,"end":595},"obj":"Chemical"},{"id":"3103","span":{"begin":566,"end":576},"obj":"Disease"}],"attributes":[{"id":"A3092","pred":"tao:has_database_id","subj":"3092","obj":"Gene:6999"},{"id":"A3093","pred":"tao:has_database_id","subj":"3093","obj":"Gene:6999"},{"id":"A3094","pred":"tao:has_database_id","subj":"3094","obj":"Gene:6999"},{"id":"A3095","pred":"tao:has_database_id","subj":"3095","obj":"Tax:2697049"},{"id":"A3096","pred":"tao:has_database_id","subj":"3096","obj":"Tax:694009"},{"id":"A3098","pred":"tao:has_database_id","subj":"3098","obj":"Tax:2697049"},{"id":"A3103","pred":"tao:has_database_id","subj":"3103","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"While vaccines are being developed to educate a person’s immune system to make their own nAbs against SARS-CoV-2, there is interest in using adoptive transfer of nAbs as a therapeutic approach (Figure 6D). This strategy has already proven to be effective against SARS-CoV-1 (Cao et al., 2010, Ho et al., 2005, ter Meulen et al., 2004, Park et al., 2020, Sui et al., 2004, Zhu et al., 2007) and MERS-CoV (Forni et al., 2015, Jia et al., 2019, Ying et al., 2015). In the case of SARS-CoV-2, these efforts are primarily centered on identifying nAbs made during natural infections or generating nAbs through animal vaccination approaches."}

{"project":"LitCovid-sentences","denotations":[{"id":"T541","span":{"begin":0,"end":205},"obj":"Sentence"},{"id":"T542","span":{"begin":206,"end":461},"obj":"Sentence"},{"id":"T543","span":{"begin":462,"end":634},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"While vaccines are being developed to educate a person’s immune system to make their own nAbs against SARS-CoV-2, there is interest in using adoptive transfer of nAbs as a therapeutic approach (Figure 6D). This strategy has already proven to be effective against SARS-CoV-1 (Cao et al., 2010, Ho et al., 2005, ter Meulen et al., 2004, Park et al., 2020, Sui et al., 2004, Zhu et al., 2007) and MERS-CoV (Forni et al., 2015, Jia et al., 2019, Ying et al., 2015). In the case of SARS-CoV-2, these efforts are primarily centered on identifying nAbs made during natural infections or generating nAbs through animal vaccination approaches."}